Lv5
1340 积分 2025-06-23 加入
Isoform switching in the CD44/ESRP1 axis as a driver of EMT and cancer stemness across tumor types
6天前
已完结
CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer
16天前
已关闭
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
1个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
2个月前
已完结
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
2个月前
已完结
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
3个月前
已完结
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
3个月前
已完结
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC
4个月前
已关闭
Emerging landscape of KRAS inhibitors in cancer treatment
4个月前
已关闭
皖公网安备34019202002308
